Early Detection and Prognostic Assessment of Cutaneous MelanomaConsensus on Optimal Practice and the Role of Gene Expression Profile Testing

Accepted for Publication: January 16, 2023.

Published Online: March 15, 2023. doi:10.1001/jamadermatol.2023.0127

Corresponding Author: John M. Kirkwood, MD, University of Pittsburgh, School of Medicine, Melanoma & Skin Cancer Disease Program, UPMC Hillman Cancer Center, UPMC Hillman Cancer Center, 5117 Centre Ave, Ste 1.32, Pittsburgh, PA 15213 (kirkwoodjm@upmc.edu).

Author Contributions: Dr Kirkwood had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Kashani-Sabet, Leachman, and Stein contributed equally to the writing of the manuscript.

Concept and design: Kirkwood, Kashani-Sabet, Leachman, Stein, Arbiser, Grant-Kels, Nelson, Tsao, Karapetyan, Savory, Sondak.

Acquisition, analysis, or interpretation of data: Kirkwood, Kashani-Sabet, Leachman, Stein, Berry, Celebi, Curiel-Lewandrowski, MD, Ferris, Grant-Kels, Grossman, Kulkarni, Marchetti, Polsky, Seiverling, Swetter, Tsao, Verdieck-Devlaeminck, Wei, Bar, Bartlett, Bolognia, Bowles, Cha, Chu, Hartman, Hawryluk, Jampel, Kheterpal, Lawson, Leming, Liebman, Ming, Sahni, Shaikh, Sober, Sondak, Spaccarelli, Usatine, Venna.

Drafting of the manuscript: Kirkwood, Kashani-Sabet, Leachman, Stein, Arbiser, Seiverling, Tsao, Verdieck-Devlaeminck, Karapetyan, Sahni.

Critical revision of the manuscript for important intellectual content: Kirkwood, Kashani-Sabet, Leachman, Stein, Arbiser, Berry, Celebi, Curiel-Lewandrowski, MD, Ferris, Grant-Kels, Grossman, Kulkarni, Marchetti, Nelson, Polsky, Seiverling, Swetter, Tsao, Wei, Bar, Bartlett, Bolognia, Bowles, Cha, Chu, Hartman, Hawryluk, Jampel, Karapetyan, Kheterpal, Lawson, Leming, Liebman, Ming, Sahni, Savory, Shaikh, Sober, Sondak, Spaccarelli, Usatine, Venna.

Obtained funding: Kirkwood.

Administrative, technical, or material support: Kirkwood, Leachman, Arbiser, Curiel-Lewandrowski, MD, Grant-Kels, Nelson, Bolognia, Bowles, Lawson, Sahni, Shaikh.

Supervision: Kirkwood, Kashani-Sabet, Leachman, Arbiser, Grant-Kels, Tsao, Kheterpal.

Other - participated in creating the data: Sober.

Conflict of Interest Disclosures: Dr Kirkwood reported grants from DermTech Inc outside the submitted work. Dr Kashani-Sabet reported stock in Melanoma Diagnostics, ownership interest in DNARX LLC, a patent issued for molecular classification of melanoma, and advisory board service for Bristol-Myers Squibb outside the submitted work. Dr Leachman reported honorarium from the Melanoma Research Foundation during the conduct of the study and research support from Castle Biosciences, Sklip Inc, Orlucent Inc, MAB, and VeriSkin Inc outside the submitted work. Dr Stein reported financial support from MoleSafe USA during the conduct of the study. Dr Berry reported personal fees from Melanoma Research Alliance during the conduct of the study as well as personal fees from Bristol Myers Squibb and Barco Inc outside the submitted work. Dr Celebi reported personal fees from NYU Grossman School of Medicine during the conduct of the study. Dr Curiel-Lewandrowski reports grants from Amgen outside the submitted work. Dr Ferris reported personal fees and grants from Derm Tech and grants from Castle Biosciences outside the submitted work. Dr Grossman reported research support from Derm Tech, Orlucent Inc, and Skin Analytics and personal fees from Orlucent Inc outside the submitted work. Dr Seiverling reported personal fees from DermaSensor Consultant for image quality review outside the submitted work. Dr Wei reported personal fees from Merck outside the submitted work. Dr Bar reported research support from Castle and personal fees from Regeneron during the conduct of the study and outside the submitted work. Dr Bartlett reported grants from SkylineDx and personal fees from Excite International LLC outside the submitted work. Dr Bolognia reported royalties from Elsevier outside the submitted work. Dr Bowles reported research support from Genentech, Amgen, Replimune, and Natera outside the submitted work. Dr Hartman reported grants from DermaSensor outside the submitted work. Dr Hawryluk reported being an author and reviewer for UpToDate outside the submitted work. Dr Savory reported being a board member for the Texas Dermatological Society. Dr Sondak reported personal fees from AMLo Biosciences, Alkermes, Bristol Myers Squibb, Genesis Drug Discovery & Development, Iovance, Merck, Novartis, Regeneron, and Ultimovacs; grants from Neogene Therapeutics and Turnstone; and nonfinancial support from SkylineDX outside the submitted work. No other disclosures were reported.

Funding/Support: The funding for the administration and facilitation of the consensus development conference and the development of thismanuscript was provided by Dermtech Inc in an unrestricted award that was administratively overseen by the Melanoma Research Foundation and managed and executed at UPMC by the principal investigato (Dr Kirkwood). DermTech was not involved in the preparation or editing of the manuscript.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.